AffyImmune Therapeutics

AffyImmune Therapeutics is a biopharmaceutical company focused on enhancing the safety and efficacy of Chimeric Antigen Receptor (CAR) T cell therapy for solid tumors. By employing a proprietary technology that utilizes genetically engineered immune cells, the company aims to extend the application of CAR-T therapies to solid tumors. This innovative approach involves tuning the affinity of these therapies from picomolar to micromolar levels, which may help reduce on-target off-tumor toxicity, thereby improving treatment outcomes for patients with cancer.